Cotempla XR-ODT™ (methylphenidate) – New drug approval
June 19, 2017 – Neos Therapeutics announced the FDA approval of Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets for the treatment of attention deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age.
Top